Table 3 Tumoral TIM-3 expression and mismatch repair loss patterns in non-methylated mismatch-repair deficient carcinomas, n/N (%)

From: TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers

 

+TIM-3 (≥1%) in tumor cells

MSH6 loss

8/8 (100%)

MSH6/MLH1/PMS2 loss

1/1 (100%)

MSH2/MSH6 Dual loss

8/12 (67%)

PMS2 loss

2/4 (50%)

Back to article page